MedicalNeed
New Member
A revolutionary new book that reframes the marijuana* debate in a new conversation on the public policy task of cannabis management.
“It is time to talk about American drug policy,” writes psychiatrist and former state mental health director Christopher Glenn Fichtner, M.D. But this new conversation requires a new vocabulary: “the demonization of marijuana has been so extreme, and the conceptual distortions of American marijuana policy so profound, that the word ‘marijuana’ itself is no longer serviceable for public conversation.”
Praise for Cannabinomics
“… an incisive administrative and clinical analysis that dissects the failure of American drug policy and charts a bright future for medicinal cannabis.”
David Bearman, M.D., Founding Board Member and Vice President, American Academy of Cannabinoid Medicine; Author of Demons, Discrimination and Dollars: A Brief History of the Origins of American Drug Policy (Prosperity Press, 2008)
“… a must read for anyone interested in cannabis policy reform. A highly experienced psychiatrist has put the facts, myths and opinions that swirl around drug policy reform into one comprehensive book that allows the reader to see through the fog of the drug war rhetoric and partisan propaganda.”
David G. Ostrow, M.D., Ph.D., Senior Research Associate, Ogburn-Stouffer Center for Organizational Research, NORC at the University of Chicago; Founding Principle Investigator & Chair, Behavioral Working Group of the Multicenter AIDS Cohort Study; Chair, Scientific Advisory Board, Americans for Safe Access
* Marijuana is an “Americanism” for the dried flowers and leaves of the Cannabis sativa or Cannabis indica plant
YouTube - The Marijuana Policy Tipping Point: A conversation with author Christopher Fichtner, M.D.
NewsHawk: MedicalNeed:420 MAGAZINE
Source: cannabinomics | home page
Author: Christopher Glenn Fichtner, M.D.
Contact: cannabinomics | contact information
Copyright: 2010 Christopher Glenn Fichtner
Website: cannabinomics | home page
“It is time to talk about American drug policy,” writes psychiatrist and former state mental health director Christopher Glenn Fichtner, M.D. But this new conversation requires a new vocabulary: “the demonization of marijuana has been so extreme, and the conceptual distortions of American marijuana policy so profound, that the word ‘marijuana’ itself is no longer serviceable for public conversation.”
Praise for Cannabinomics
“… an incisive administrative and clinical analysis that dissects the failure of American drug policy and charts a bright future for medicinal cannabis.”
David Bearman, M.D., Founding Board Member and Vice President, American Academy of Cannabinoid Medicine; Author of Demons, Discrimination and Dollars: A Brief History of the Origins of American Drug Policy (Prosperity Press, 2008)
“… a must read for anyone interested in cannabis policy reform. A highly experienced psychiatrist has put the facts, myths and opinions that swirl around drug policy reform into one comprehensive book that allows the reader to see through the fog of the drug war rhetoric and partisan propaganda.”
David G. Ostrow, M.D., Ph.D., Senior Research Associate, Ogburn-Stouffer Center for Organizational Research, NORC at the University of Chicago; Founding Principle Investigator & Chair, Behavioral Working Group of the Multicenter AIDS Cohort Study; Chair, Scientific Advisory Board, Americans for Safe Access
* Marijuana is an “Americanism” for the dried flowers and leaves of the Cannabis sativa or Cannabis indica plant
YouTube - The Marijuana Policy Tipping Point: A conversation with author Christopher Fichtner, M.D.
NewsHawk: MedicalNeed:420 MAGAZINE
Source: cannabinomics | home page
Author: Christopher Glenn Fichtner, M.D.
Contact: cannabinomics | contact information
Copyright: 2010 Christopher Glenn Fichtner
Website: cannabinomics | home page
